Cargando…
Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis
Early diagnosis along with new drugs targeted to cancer receptors and immunocheckpoints have improved breast cancer survival. However, full remission remains elusive for metastatic breast cancer due to dose-limiting toxicities of heavily used, highly potent drug combinations such as gemcitabine and...
Autores principales: | Mu, Qingxin, Yu, Jesse, Griffin, James I., Wu, Yan, Zhu, Linxi, McConnachie, Lisa A., Ho, Rodney J. Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059902/ https://www.ncbi.nlm.nih.gov/pubmed/32142553 http://dx.doi.org/10.1371/journal.pone.0228557 |
Ejemplares similares
-
ICAM-1 Targeted Drug Combination Nanoparticles Enhanced Gemcitabine-Paclitaxel Exposure and Breast Cancer Suppression in Mouse Models
por: Zhu, Linxi, et al.
Publicado: (2021) -
Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure
por: Griffin, James, et al.
Publicado: (2023) -
Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma
por: Kraft, John C., et al.
Publicado: (2017) -
Total Reactive Isocyanate Group (TRIG) Measurement: A Commentary
por: McConnachie, Glen, et al.
Publicado: (2023) -
SaeboGlove therapy for
upper limb disability and
severe hand
impairment after stroke (SUSHI): Study protocol for a
randomised controlled trial
por: Alexander, Jen, et al.
Publicado: (2021)